Key Highlights

  • Pulmonx rose 27.27% to $2.52 after third-quarter revenue grew 6% to $22.8 million.
  • PacBio was trading 22.24% higher at $3.00 with no dated company release, ahead of third-quarter results on November 4.
  • Onconetix was trading 18.02% higher at $0.56, with a 1-for-10 reverse split effective November 6.
  • GlucoTrack faces a Nasdaq closing-bid condition of at least $1.00 through November 9, 2026.
  • EyePoint holds about $118 million of cash against a market value near $33.6 million (calculated).

Which Diagnostics and Medical-Device Stocks Are Trading Higher on October 28?

Six healthcare names were trading higher on Wednesday, October 28, 2026. Pulmonx (NASDAQ:LUNG) was trading 27.27% higher at $2.52, Pacific Biosciences of California (NASDAQ:PACB) 22.24% higher at $3.00 and Onconetix (NASDAQ:ONCO) 18.02% higher at $0.56. GlucoTrack (NASDAQ:GCTK) was trading 15.50% higher at $1.98, EyePoint (NASDAQ:EYPT) 7.93% higher at $0.39 and Nautilus Biotechnology (NASDAQ:NAUT) 7.73% higher at $3.11.

Pulmonx and Nautilus reported quarterly results on October 27, while the other four had no dated company release explaining the move. EyePoint is a retinal drug developer and Onconetix sells a prostate cancer blood test alongside a pending robotics deal, so both fit the group only loosely. Sections run from the largest move to the smallest.

Pulmonx: Did the Third-Quarter Report Drive the 27.27% Jump?

Pulmonx was trading 27.27% higher at $2.52, implying a prior close of about $1.98 (calculated). The likely catalyst is the October 27 third-quarter release, an inference from timing since the release does not discuss the share price. Revenue rose 6% to $22.8 million, the net loss narrowed to $8.4 million, or $0.19 per share, from $14.0 million, and full-year revenue guidance of $90 million to $92 million was held. The company sells the Zephyr Endobronchial Valve for severe emphysema, and China contributed no revenue because the distributor has not resumed orders. Cash was $52.7 million at September 30, 2026, down from $69.8 million at December 31, 2025, against about $37.8 million of debt.

Pacific Biosciences of California: What Is Behind a 22.24% Move With No Dated Release?

PacBio was trading 22.24% higher at $3.00, implying a prior close near $2.45 (calculated), and no dated company release accompanied the move. The company makes DNA sequencing systems built around long-read SMRT technology. It announced a multi-year collaboration with Verily Health on October 19. Second-quarter revenue was $39.0 million, full-year guidance was cut to $155 million to $165 million, and cash and investments of $236.9 million at June 30 compare with $644.3 million of convertible senior notes. Latest available short-interest data show 47.22 million shares sold short, or 15.53% of float, with 4.51 days to cover. Third-quarter results are due November 4, 2026.

Onconetix: Why Is a Sub-$1 Stock Jumping Ahead of a Reverse Split?

Onconetix was trading 18.02% higher at $0.56, from an implied prior close near $0.47 (calculated), and no dated company release on October 28 accompanies the advance. On October 26 it announced a 1-for-10 reverse stock split, expected at 12:01 a.m. Eastern on November 6, which would cut about 5,886,774 shares to roughly 588,677. Its Proclarix prostate cancer test depends on Labcorp (NYSE:LH) for sales, and first-half revenue was $38,577. The all-stock Realbotix acquisition is pending, with $3.0 million of an up to $5.0 million bridge facility advanced. Cash was $5.94 million at June 30, and the latest quarterly filing carries a going-concern warning.

GlucoTrack: Why Is the Implantable Glucose Monitor Developer Up 15.50% With No New Release?

GlucoTrack was trading 15.50% higher at $1.98, from an implied prior close near $1.71 (calculated), and no release dated October 27 or 28 accompanied the move. The company is developing an implantable continuous glucose monitor and is working through the FDA pre-submission process before resubmitting a U.S. device application. It had 2,368,237 shares outstanding in early October after a 1-for-15 reverse split, and a filing registers up to 43,223,705 shares for resale under a $50.0 million equity line. Cash was about $3.9 million at March 31, 2026, with a going-concern warning, and a Nasdaq panel requires a closing bid of at least $1.00 through November 9.

EyePoint: Can About $118 Million in Cash Support a Rebound After the LUCIA Miss?

EyePoint was trading 7.93% higher at $0.39, with no new company release dated today. On October 19 the Phase 3 LUCIA trial of DURAVYU for wet age-related macular degeneration missed its primary endpoint, and shares fell from $2.99 to roughly $0.44. The company is cutting about 53% of staff, with annualized savings of about $30 million. Cash and short-term investments were about $118 million at September 30, 2026, roughly $1.37 per share (calculated). Short interest for the October 15 settlement date was 21,260,757 shares, about 24.7% of shares outstanding (calculated), with 8.07 days to cover. Diabetic macular edema trial data are expected in the fourth quarter of 2027.

Nautilus Biotechnology: Is Tuesday's Quarterly Report Behind the 7.73% Climb?

Nautilus was trading 7.73% higher at $3.11, implying a prior close near $2.89 (calculated), one session after its October 27 report, and no separate announcement was dated today. The third-quarter net loss was $15.636 million, or $0.12 per share, narrower than an estimated $0.14 loss. Cash and investments were $114.3 million at September 30, down about $41.8 million from the end of 2025. The company is developing a protein-mapping platform whose Voyager instrument is not yet sold, with availability planned for mid-2027. Revenue was $234,000, mostly grants.

Diagnostics and Medical-Device Stocks Compared: Move Size, Dollar Gains and Cash

Pulmonx's 27.27% gain is 19.54 percentage points above Nautilus at 7.73% (calculated). Pulmonx and PacBio show nearly the same dollar gain, about $0.54 and $0.55 per share on the implied prior closes, even though PacBio's percentage move is 5.03 points smaller (calculated).

Balance sheets differ widely, and dates vary. At September 30, EyePoint's about $118 million of cash is $3.7 million above Nautilus at $114.3 million, and about 3.5 times its roughly $33.6 million market value (calculated). PacBio's $644.3 million of convertible notes exceed its $236.9 million of cash and investments by $407.4 million (calculated, June 30 balance sheet).

What to Watch Next: Key Dates From November 4 to November 12

PacBio reports third-quarter results on November 4, 2026, and Onconetix's reverse split is expected on November 6. GlucoTrack's Nasdaq bid-price condition runs through November 9, and EyePoint's next earnings report is estimated for around November 9. Onconetix's third-quarter report is estimated for around November 12. Pulmonx has not announced a fourth-quarter date and must reach roughly $23.8 million to $25.8 million of quarterly revenue (calculated) to meet its full-year range.